SAN FRANCISCO, Oct. 10 - Lexicon Genetics has licensed its gene-targeting isogenic DNA technology to US drug giant Pfizer, the companies announced on Wednesday.

Financial details of the agreement were not disclosed.

The non-exclusive internal research-use license is the second The Woodlands, Texas-based Lexicon has licensed to Pfizer, which also holds a non-exclusive license from Lexicon for internal research use of Lexicon's positive-negative selection technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more